Search results
Jump to navigation
Jump to search
Google site results
Loading...
Wiki results
Page title matches
- 0 members (0 subcategories, 0 files) - 11:42, 15 January 2021
Page text matches
- ...h an interest in clinical cytogenetics, molecular genetics and genomics in cancer. [[Contact us]] for more information.''' [[File:Circos.png|100px|link=Main_Page]] '''Cancer Genomes''' [[Hematologoic and Lymphoid]] | [[Solid Tumors]] | [[CNS]] | [[P7 KB (905 words) - 22:59, 20 November 2017
- == Genes == * Cancer Genes A10 KB (1,089 words) - 22:30, 20 November 2017
- ...h an interest in clinical cytogenetics, molecular genetics and genomics in cancer.''' ...ermission from the copyright holder, ©International Agency for Research on Cancer.''|alt=]]7 KB (1,032 words) - 10:43, 5 March 2024
- ==General Disease Overview / Description of Cancer Category== ...blastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged|B-ALL with t(v;11q23.3); KMT2A-Rearranged]]3 KB (412 words) - 12:36, 3 November 2023
- {{DISPLAYTITLE:Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged}} ==Cancer Category/Type==9 KB (1,384 words) - 16:30, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,372 words) - 12:36, 3 November 2023
- == Genes Involved == ...t and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes Chromosome Cancer 15:38–47CrossRef4 KB (537 words) - 21:44, 20 July 2016
- ==General Disease Overview / Description of Cancer Category== *[[B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged]]3 KB (349 words) - 12:37, 3 November 2023
- "KIT Proto-Oncogene Receptor Tyrosine Kinase"; "V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog"; PBT; "Stem C ==Cancer Category/Type==7 KB (1,047 words) - 14:32, 12 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,310 words) - 12:49, 3 November 2023
- ==General Disease Overview / Description of Cancer Category== ...5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B-ALL with t(v;11q23.3); KMT2A-Rearranged]]3 KB (430 words) - 16:30, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,358 words) - 16:40, 4 December 2023
- ...page can be found at [[HAEM4:Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged]]. ==Cancer Category / Type==19 KB (2,659 words) - 14:32, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,431 words) - 12:56, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,475 words) - 13:59, 3 November 2023
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,285 words) - 15:49, 13 September 2019
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,285 words) - 16:56, 8 August 2020
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,282 words) - 11:49, 14 June 2019
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,397 words) - 12:33, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,774 words) - 12:56, 3 November 2023
- ...>Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov;6(6):571-579</ref> ...ton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 8;26(3):319-30.</ref>3 KB (421 words) - 11:29, 22 August 2016
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==11 KB (1,435 words) - 13:46, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,816 words) - 14:00, 3 November 2023
- ...Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics. |'''Genes'''17 KB (2,298 words) - 16:42, 22 April 2021
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,669 words) - 12:40, 3 November 2023
- ==Cancer Category/Type== ...scular endothelial growth factor (''VEGF'') (Merdzhanova et al., 2010). In cancer, ''SRSF2'' variants have been implicated in leukemia and myeloid disorders16 KB (2,281 words) - 14:50, 12 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,320 words) - 12:39, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,705 words) - 12:38, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,340 words) - 12:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,711 words) - 16:34, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,721 words) - 13:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,265 words) - 12:54, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,380 words) - 16:33, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,383 words) - 16:39, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,304 words) - 16:43, 4 December 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==6 KB (814 words) - 12:53, 3 November 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==6 KB (814 words) - 12:53, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,044 words) - 10:09, 27 February 2024
- Thank you for volunteering to help curate the Compendium of Cancer Genome Aberrations (CCGA)! Your help will make this resource a valuable to ...“Disease pages”. The CCGA is especially interested in the curation fusion genes/mutations that arise in disease, esp. in the hematological cancers. Howeve7 KB (1,171 words) - 17:30, 23 April 2019
- ...ed from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics. ...urvival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer J 2013;3:e155.[https://www.ncbi.nlm.nih.gov/pubmed/24185502]</ref><ref name38 KB (5,270 words) - 17:10, 30 April 2020
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,651 words) - 14:40, 13 December 2023
- ==Cancer Category/Type== Breast Cancer / Epithelial Tumours of the Breast19 KB (2,737 words) - 13:17, 29 February 2024
- {{DISPLAYTITLE:B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged}} ==Cancer Category/Type==6 KB (910 words) - 13:48, 3 November 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==13 KB (1,772 words) - 12:52, 3 November 2023
- ==Cancer Category/Type== ...ET2 and WT1 physically interact, suggesting overlapping pathways for these genes in AML (Wang et al., 2015). ''TET2'' mutations increase the response of low26 KB (3,824 words) - 15:01, 12 December 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==13 KB (1,811 words) - 13:58, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,693 words) - 12:30, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==6 KB (851 words) - 12:46, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,734 words) - 13:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,022 words) - 12:31, 3 November 2023